Mira Pharmaceuticals (MIRA) Equity Average (2022 - 2025)

Mira Pharmaceuticals (MIRA) has 4 years of Equity Average data on file, last reported at $9.0 million in Q4 2025.

• Quarterly Equity Average rose 210.04% year-over-year to $9.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.0 million (up 210.04% YoY) and the FY2025 annual result came in at $6.3 million, up 91.66% from the prior year.
• Equity Average advanced to $9.0 million in Q4 2025 per MIRA's latest filing, from $4.0 million in the prior quarter.
• The five-year high for Equity Average was $9.0 million in Q4 2025, with the low at -$1.2 million in Q1 2023.
• Average Equity Average over 4 years is $2.9 million, with a median of $2.9 million recorded in 2024.
• Year-over-year, Equity Average soared 4628.8% in 2023 and sank 65.33% in 2025.
• Mira Pharmaceuticals' Equity Average stood at -$137891.5 in 2022, then soared by 4628.8% to $6.2 million in 2023, then tumbled by 53.77% to $2.9 million in 2024, then surged by 210.04% to $9.0 million in 2025.
• Business Quant data shows MIRA's Equity Average at $9.0 million in Q4 2025, $4.0 million in Q3 2025, and $932012.0 in Q2 2025.